Trial Profile
A phase I dose-escalation study of flavopiridol [alvocidib] (NSC 649890) administered as a 30 minute loading dose followed by a 4-hour infusion in patients with B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) following cytoreduction with chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Alvocidib (Primary) ; Allopurinol; Ciprofloxacin; Dexamethasone; Dexamethasone; Pegfilgrastim; Valaciclovir
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Apr 2013 Planned End Date changed from 1 Jan 2100 to 1 Jun 2013 as reported by ClinicalTrials.gov.